<DOC>
	<DOCNO>NCT00660400</DOCNO>
	<brief_summary>The purpose study find treat people high-risk myelodysplastic syndrome ( MDS ) 5-Azacitidine ( Vidaza ) prior allogeneic hematopoietic cell transplant ( HCT ) helpful prevent myelodysplastic syndrome come back . In previous research , 5-Azacitidine appear help bone marrow patient MDS begin function normally . This mean bone marrow cell grow work way meant . 5-Azacitidine approve Food Drug Administration ( FDA ) treatment MDS . The effect 5-Azacitidine patient receive hematopoietic cell transplant study .</brief_summary>
	<brief_title>Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell Transplant</brief_title>
	<detailed_description>RESEARCH PLAN - This single-center prospective trial - Patients high risk MDS potentially eligible HCT enrol . - A donor search initiate , 5-Azacitidine give per standard practice . - 5-Azacitidine dose 75 mg/M^2/day subcutaneously standard practice ( generally 7 day per monthly cycle , alteration occur depend clinical laboratory parameter ) . - Patients suitable donor find continue 5-Azacitidine per standard treatment . These patient follow progression MDS acute myelogenous leukemia ( AML ) death , one year . - If suitable donor obtain , patient proceed HCT . The HCT condition regimen dictate Blood Marrow Transplant ( BMT ) physician . While wait HCT , additional cycle 5-Azacitidine may give . Pre-HCT condition regimen therapy begin 8 week less 4 week last administration 5-Azacitidine . - As number cycle 5-Azacitidine standardized retrospective review patient note indicated benefit ANY exposure 5-Azacitidine , actual number cycle 5-Azacitidine deliver specify . In addition , high risk MDS patient average time death 0.4 year , delay HCT available avoid . - A bone marrow biopsy perform reassess disease response therapy last cycle 5-Azacitidine transplant , fourth cycle 5-Azacitidine , whichever come first . Note biopsy time biopsy standard evaluation procedure . - Donor progenitor cell collection prescribe BMT Attending Physician . HCT - The patient undergo HCT designate per attend BMT physician . - Supportive care base institutional guideline , Stem cell collection , process laboratory study Stem cell collection , process laboratory study - Graft assessment , processing , characterization do per institutional guideline - Chimerism test obtain document post-transplant engraftment , per standard practice .</detailed_description>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Potential candidate HCT . Histologically confirm diagnosis pathologic review previous diagnosis highrisk myelodysplastic syndrome ( MDS ) : International Prognostic Scoring System ( IPSS ) &gt; 1 AMLMDS treatment related MDS . Serum bilirubin level ≤1.5 time upper limit normal ( ULN ) range laboratory . Higher level acceptable attribute active hemolysis ineffective erythropoiesis ; Serum glutamicoxaloacetic transaminase ( SGOT ) [ aspartate aminotransferase ( AST ) ] serum glutamic pyruvic transaminase ( SGPT ) [ alanine aminotransferase ( ALT ) ] level ≤2 x ULN . Serum creatinine level ≤1.5 x ULN Karnofsky performance status great equal 70 % Signed informed consent form accordance institutional policy Known suspected hypersensitivity Vidaza mannitol Pregnant lactate woman Human immunodeficiency virus ( HIV ) seropositive , confirm nucleic acid amplification test ( NAT ) Active central nervous system ( CNS ) malignancy Active infection History presence primary hepatoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Myeloid</keyword>
	<keyword>Monocytic</keyword>
</DOC>